Market closed
Fulgent Genetics/$FLGT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Fulgent Genetics
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Ticker
$FLGT
Sector
Trading on
Industry
Health Care Providers & Services
Headquarters
Employees
1,184
Website
Fulgent Genetics Metrics
BasicAdvanced
$599M
Market cap
-
P/E ratio
-$5.50
EPS
1.51
Beta
-
Dividend rate
Price and volume
Market cap
$599M
Beta
1.51
52-week high
$30.68
52-week low
$16.56
Average daily volume
279K
Financial strength
Current ratio
4.413
Quick ratio
3.757
Long term debt to equity
0.67
Total debt to equity
0.876
Management effectiveness
Return on assets (TTM)
-4.15%
Return on equity (TTM)
-14.35%
Valuation
Price to revenue (TTM)
2.116
Price to book
0.53
Price to tangible book (TTM)
0.61
Price to free cash flow (TTM)
-20.499
Growth
Revenue change (TTM)
-3.02%
Earnings per share change (TTM)
157.03%
3-year revenue growth (CAGR)
-35.52%
3-year earnings per share growth (CAGR)
-33.93%
What the Analysts think about Fulgent Genetics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Fulgent Genetics stock.
Fulgent Genetics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Fulgent Genetics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Fulgent Genetics News
AllArticlesVideos
Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1
Business Wire·1 month ago
Fulgent Genetics: An NCAV Pick With Profit And Growth Potential
Seeking Alpha·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Fulgent Genetics stock?
Fulgent Genetics (FLGT) has a market cap of $599M as of December 15, 2024.
What is the P/E ratio for Fulgent Genetics stock?
The price to earnings (P/E) ratio for Fulgent Genetics (FLGT) stock is 0 as of December 15, 2024.
Does Fulgent Genetics stock pay dividends?
No, Fulgent Genetics (FLGT) stock does not pay dividends to its shareholders as of December 15, 2024.
When is the next Fulgent Genetics dividend payment date?
Fulgent Genetics (FLGT) stock does not pay dividends to its shareholders.
What is the beta indicator for Fulgent Genetics?
Fulgent Genetics (FLGT) has a beta rating of 1.51. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.